Tumor Necrosis Factor Inhibitor Drugs Market Size, Share & Trends Analysis Report By Product (Humira, Enbrel Remicade, Simponi/Simponi Aria, Cimzia), By Application, By Sales Channel, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global tumor necrosis factor inhibitor drugs market size was valued at USD 24.9 billion in 2024 and is anticipated to grow at a CAGR of 2.2% from 2025 to 2030. The market growth is attributed to the increasing occurrence of autoimmune diseases, continuous development of novel TNF inhibitors, and awareness of these conditions. In addition, improved healthcare infrastructure, evolution in TNF inhibitors, and patient-centric approaches are important drivers of expansion.

Tumor necrosis factor (TNF) inhibitors are drugs used to treat autoimmune illnesses and inflammatory diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. These diseases occur when the immune system mistakenly attacks the body's tissues. TNF inhibitors function by preventing the action of tumor necrosis factor, which causes inflammation. This helps to reduce pain and provides relief and quality of life by easing it.

The demand for TNF inhibitors is rising as autoimmune illnesses become more common. As more people are diagnosed and know the cause of the disease, the need for proper treatment options increases. In addition, as the population ages, more people are expected to be affected by these diseases. Further, adding and developing new drug formulations will drive the market. As TNF indicators and combination medicines, they offer better efficiency and fewer side effects.  

Moreover, the therapy environment is changing with the emergence of biosimilars. These are identical copies of existing replicas of already available biological drugs, eventually increasing the availability and competition in the market. Clinical guidelines and research are growing and supporting the usage of TNF inhibitors for a wide range of related diseases. The market is expected to continuously grow with the ongoing clinical trials exploring new uses for TNF inhibitors and improved patient outcomes.  

Global regulatory bodies also emphasize the value of investing in research and development for autoimmune diseases, which is expected to lead to more innovative treatments in the coming years. Ultimately, a bigger patient base, improved drug therapies, and more research projects contribute to the TNF inhibitor market's growth, offering hope for improved autoimmune disease management. 

Product Insights

Humira led the product segment, dominating the market with the largest revenue share of 40.5% in 2024 in TNF inhibitors due to its proven effectiveness in treating various autoimmune disorders, which fostered strong trust among patients and healthcare providers. The drug's versatility, approved for conditions such as rheumatoid arthritis and Crohn's disease, allows it to serve a wide range of patients, increasing its market share. Humira's established market presence and the depth of its clinical data have made it difficult for rivals to make a significant presence.

The Biosimilars segment is expected to grow at a CAGR of 15.5% over the forecast period, driven by various factors that address changing healthcare needs, affordable substitutes, and expensive biologics such as Humira. Patients and healthcare professionals are keen to investigate more biosimilars at low costs, and more biosimilars are approved as patents expire. The growing focus on value-based care promotes the use of biosimilars, as they can help healthcare systems manage costs while maintaining the treatment quality. As a result, the biosimilar segment is expected to grow and take a bigger chunk of the market.

Application Insights

Rheumatoid arthritis dominated the market and accounted for the largest revenue share of 17.51% in 2024 due to its high prevalence globally. TNF inhibitors depend on RA treatment due to their ability to reduce symptoms and slow down disease spread, resulting in a prevalent spread in the healthcare sector. The competitive environment plays a crucial role in focusing on RA, as pharmaceutical companies invest largely in patient education and marketing, with healthcare providers suggesting this as a first-line option. As a result, many patients experience significant relief from symptoms due to clinical support, treatment guidelines, and preventing long term joint damage.

Psoriasis is expected to grow at a CAGR of 3.1% over the forecast period from 2024 to 2030. This trend can be attributed to factors such as the growing understanding of diseases, improved diagnosis, and awareness among patients and healthcare providers. Aging populations, exposure to pollutants, lifestyle influences, and emerging innovations have fueled the market's expansion.

Sales Channel Insights

TNF inhibitors are sold through three main sales channels: hospital pharmacy, specialty pharmacy, and online pharmacy. Hospital pharmacies contributed the largest revenue share, 40% in 2024, due to being most patients' first preference and primary contact. Managing these types of diseases requires specialized care, inbuilt facilities, expertise, emergency medical treatment, collaboration with manufacturers, and tie-ups with pharmacies for cost efficiency, which hospitals easily provide. 

Online pharmacy is also expected to grow at the highest CAGR of 3.7% over the forecasted period till 2030. Online platforms are in demand due to easy access to digital platforms, smooth ordering, in time delivery, and affordable pricing, making them appealing and providing privacy and ease, particularly for sensitive diseases such as rheumatoid arthritis and psoriasis.

Regional Insights

North America tumor necrosis factor (TNF) inhibitor drugs marketdominated the global market and accounted for the largest revenue share of 37.3% in 2024 due to increasing population, rise in autoimmune disorders, and effective treatments have driven the market. Further, the introduction of advanced biological therapies and personalized treatment plans has stimulated further growth. The presence of dominant pharmaceutical companies, research and development initiatives, and government policies have driven the growth.

U.S. Tumor Necrosis Factor Inhibitor Drugs Market Trends

The tumor necrosis factor inhibitor drugs market in the U.S. dominated North America, with the largest revenue share in 2024. This is largely attributed to the growth of autoimmune diseases, the big patient pool, and the facilitation of TNF inhibitors' importance as advanced therapies. Personalized treatment, the presence of major key players in pharmaceuticals, and an established healthcare system have played a crucial role in maintaining market growth and demand.

Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market Trends

Asia Pacific tumor necrosis factor inhibitor drugs marketis expected to grow at a CAGR of 4.5% over the forecast period. This growth is driven by the increasing number of autoimmune diseases and the rising awareness of effective treatment options. Improved healthcare infrastructure and accessibility in the region further support the demand for these biologic therapies.

In addition, the integration of advanced therapy solutions and the introduction of innovative drugs tailored to the population's unique needs are enhancing treatment outcomes. As healthcare providers and patients recognize the benefits of TNF inhibitors, the market is poised for strong growth.

The tumor necrosis factor inhibitor drug market in China is expected to grow significantly due to rapid urbanization and lifestyle changes, government initiatives to upgrade the healthcare sector due to the increase in population, and awareness to seek appropriate diagnosis. Further, the rise of conventional Chinese medicines is gaining drive, and local pharmaceutical companies are quickly growing with the introduction of new procedures.

Key Tumor Necrosis Factor Inhibitor Drugs Company Insights

Some key players in the market are AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., and others. These companies constantly invest in product innovation, such as developing biosimilars, focusing on personalized treatment methods to meet patient needs and enhance treatment productivity and satisfaction. Collaborative research initiatives with healthcare specialists and research institutes drive innovation and integration, which improves the outcomes so that they can stay at the forefront of industry trends.                                                                                       

• AbbVie Inc. has been a prominent market leader for years and is well known for its ability to treat various autoimmune diseases, including rheumatoid arthritis and Crohn's disease. AbbVie has introduced Humira, one of the best-selling drugs globally. It has positioned itself for many years, so it has a vast clinical database, which helps it adapt to the changing world with its research and development focusing on new therapies. This eventually allowed it to capitalize on emerging markets, and its market influence and physician acceptance also increased.

• Johnson & Johnson Services’ major manufactured product is Remicade, which has been a cornerstone in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. The company's long history and reputation contribute to its market growth and strength. By constantly investing in research and development, it finds new ways to develop new interpretations that can improve patient results and mark its presence as a prominent player in the market.

Recent Developments

• January 09, 2024, AbbVie Launches PRODUODOPA (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union. -PRODUODOPA is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's disease. PRODUODOPA demonstrated sustained improvements in "Off" time (when symptoms return between medication doses), "On" time (when symptoms are controlled) without dyskinesia (involuntary movement), and morning akinesia ("Off" time upon waking). 

• In October 2024, TREMFYA (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn’s disease and ulcerative colitis TREMFYAis now U.S. FDA-approved for ulcerative colitis and under review for Crohn’s disease. TREMFYA is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn’s disease, inclusive of those who are biologic-naïve and biologic-refractory Ninety percent more biologic-naïve patients and three times more biologic-refractory patients with ulcerative colitis achieved endoscopic remission with TREMFYA  

Tumor Necrosis Factor Inhibitor Drugs Market Report Scope

Global Tumor Necrosis Factor Inhibitor Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the global tumor necrosis factor inhibitor drugs market report based on product, application, sales channel, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Humira

  • Enbrel

  • Remicade

  • Simponi/Simponi Aria

  • Cimzia

  • Biosimilars

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Rheumatoid Arthritis

  • Psoriasis

  • Psoriatic Arthritis

  • Ulcerative Colitis

  • Crohn’s Disease

  • Ankylosing Spondylitis

  • Juvenile Idiopathic Arthritis

  • Hidradenitis suppurativa

  • Others

• Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Speciality Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE 

    • Kuwait